Parallel evolution of reduced cancer risk and tumor suppressor duplications in Xenarthra

  1. Juan Manuel Vazquez
  2. Maria T Pena
  3. Baaqeyah Muhammad
  4. Morgan Kraft
  5. Linda B Adams
  6. Vincent J Lynch  Is a corresponding author
  1. University of California, Berkeley, United States
  2. United States Department of Health and Human Services, United States
  3. University at Buffalo, State University of New York, United States

Abstract

The risk of developing cancer is correlated with body size and lifespan within species, but there is no correlation between cancer and either body size or lifespan between species indicating that large, long-lived species have evolved enhanced cancer protection mechanisms. Previously we showed that several large bodied Afrotherian lineages evolved reduced intrinsic cancer risk, particularly elephants and their extinct relatives (Proboscideans), coincident with pervasive duplication of tumor suppressor genes (Vazquez and Lynch 2021). Unexpectedly, we also found that Xenarthrans (sloths, armadillos, and anteaters) evolved very low intrinsic cancer risk. Here, we show that: 1) several Xenarthran lineages independently evolved large bodies, long lifespans, and reduced intrinsic cancer risk; 2) the reduced cancer risk in the stem lineages of Xenarthra and Pilosa coincided with bursts of tumor suppressor gene duplications; 3) cells from sloths proliferate extremely slowly while Xenarthran cells induce apoptosis at very low doses of DNA damaging agents; and 4) the prevalence of cancer is extremely low Xenarthrans, and cancer is nearly absent from armadillos. These data implicate the duplication of tumor suppressor genes in the evolution of remarkably large body sizes and decreased cancer risk in Xenarthrans and suggest they are a remarkably cancer resistant group of mammals.

Data availability

All data generated or analysed during this study are included in the manuscript, supporting files, and data.

Article and author information

Author details

  1. Juan Manuel Vazquez

    Department of Integrative Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8341-2390
  2. Maria T Pena

    National Hansen's Disease Program, United States Department of Health and Human Services, Baton Rouge, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Baaqeyah Muhammad

    Department of Biological Sciences, University at Buffalo, State University of New York, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Morgan Kraft

    Department of Biological Sciences, University at Buffalo, State University of New York, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Linda B Adams

    National Hansen's Disease Program, United States Department of Health and Human Services, Baton Rouge, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Vincent J Lynch

    Department of Biological Sciences, University at Buffalo, State University of New York, Buffalo, United States
    For correspondence
    vjlynch@buffalo.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5311-3824

Funding

Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AAI15006)

  • Maria T Pena
  • Linda B Adams

National Institutes of Health (R56AG071860)

  • Vincent J Lynch

National Science Foundation (2028459)

  • Vincent J Lynch

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Juan Manuel Vazquez
  2. Maria T Pena
  3. Baaqeyah Muhammad
  4. Morgan Kraft
  5. Linda B Adams
  6. Vincent J Lynch
(2022)
Parallel evolution of reduced cancer risk and tumor suppressor duplications in Xenarthra
eLife 11:e82558.
https://doi.org/10.7554/eLife.82558

Share this article

https://doi.org/10.7554/eLife.82558

Further reading

    1. Cancer Biology
    Pierluigi Scerbo, Benjamin Tisserand ... Bertrand Ducos
    Research Article

    Why does a normal cell possibly harboring genetic mutations in oncogene or tumor suppressor genes becomes malignant and develops a tumor is a subject of intense debate. Various theories have been proposed but their experimental test has been hampered by the unpredictable and improbable malignant transformation of single cells. Here, using an optogenetic approach we permanently turn on an oncogene (KRASG12V) in a single cell of a zebrafish brain that, only in synergy with the transient co-activation of a reprogramming factor (VENTX/NANOG/OCT4), undergoes a deterministic malignant transition and robustly and reproducibly develops within 6 days into a full-blown tumor. The controlled way in which a single cell can thus be manipulated to give rise to cancer lends support to the ‘ground state theory of cancer initiation’ through ‘short-range dispersal’ of the first malignant cells preceding tumor growth.

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.